There is one clinical trial.
According to In vitro studies, ciclesonide showed good antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although some cases were reported for the clinical effectiveness of ciclesonide in the treatment of COVID-19, there is no clinical trial to evaluate the antiviral effect on the reduction of viral load in patients with COVID-19. In this study, we aimed to investigate whether ciclesonide alone or in combination with hydroxychloroquine could eradicate SARS-CoV-2 from respiratory tract earlier in patients with mild COVID-19.
Description: Viral load
Measure: Rate of SARS-CoV-2 eradication at day 14 from study enrollment Time: Hospital day 14Description: Viral load
Measure: Rate of SARS-CoV-2 eradication at day 7 from study enrollment Time: Hospital day 7Description: Viral load
Measure: Time to SARS-CoV-2 eradication (days) Time: Hospital day 1, 4, 7, 10, 14, 21Description: Viral load change
Measure: Viral load area-under-the-curve (AUC) reduction versus control Time: Hospital day 1, 4, 7, 10, 14, 21Description: Resolution of all systemic and respiratory symptoms for ≥2 consecutive days
Measure: Time to clinical improvement (days) Time: Up to 28 daysDescription: ICU admission, mechanical ventilation or death
Measure: Proportion of clinical failure Time: Up to 28 daysDescription: Number of adverse events, proportion of early discontinuance
Measure: Safety and tolerability of study drug Time: Up to 28 days